Gain Therapeutics
GANX
50 hedge funds and large institutions have $14.6M invested in Gain Therapeutics in 2026 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 9 closing their positions.
504% more call options, than puts
Call options by funds: $912K | Put options by funds: $151K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more funds holding
Funds holding: 50 → 50 (0)
0.95% less ownership
Funds ownership: 20.3% → 19.35% (-0.95%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
26% less capital inflows, than outflows
Capital inflows: $1.25M | Capital outflows: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$333K |
| 2 |
Jones Financial Companies
Des Peres,
Missouri
|
+$239K |
| 3 |
Cresset Asset Management
Chicago,
Illinois
|
+$109K |
| 4 |
Empowered Funds
Havertown,
Pennsylvania
|
+$95.3K |
| 5 |
State Street
Boston,
Massachusetts
|
+$76.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$443K |
| 2 |
Stratos Wealth Partners
Beachwood,
Ohio
|
-$406K |
| 3 |
Squarepoint
New York
|
-$277K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$143K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
-$112K |
GANX Hedge Fund Activity: Q3 2026 in Review
50 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2026, worth a combined $14.6M — down 16% from $17.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GANX positions and 9 closed out — a net gain of 1 holder — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $333K. The largest seller was Marshall Wace, cutting an estimated $443K.
- 50 institutional investors held Gain Therapeutics (GANX) as of Q3 2026, unchanged from Q2 2026.
- Funds reported $14.6M of Gain Therapeutics stock for Q3 2026, down 16% quarter-over-quarter.
- 10 funds opened new Gain Therapeutics positions in Q3 2026 and 9 closed out, a net change of +1 holder.
- The largest Gain Therapeutics buyer in Q3 2026 was Renaissance Technologies, an estimated $333K added.
- The largest Gain Therapeutics seller in Q3 2026 was Marshall Wace, an estimated $443K sold.
Based on aggregated 13F filings for Q3 2026.